Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR T-cells for Refractory SLE
NCT05030779Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in systemic lupus erythematosus (SLE), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 90 days. Status: unknown.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05030779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030779.